A group of scientists from University Hospital of Lausanne (Switzerland) and the Federal Polytechnic School, from the same Swiss city, discovered a monoclonal antibody that would be able to neutralize all variants of the coronavirus discovered and registered at the time.
The finding, published in the magazine Cell Reports, details that this antibody has been discovered isolating lymphocytes of patients already infected with coronavirus. This antibody blocks coronavirus proteins, preventing them from infecting lung cells.
With this antibody the road to COVID-19 disease would be slammed shut as the virus replication process is stopped. In turn, this monoclonal antibody provides a protection of at least 6 months, being even greater than other treatments.
For now, it is expected that clinical trials with a drug based on these antibodies start in late 2022.